Pharmacogenetic studies with oral anticoagulants. Genomewide association studies in vitamin K antagonist and direct oral anticoagulants

Natalia Cullell, Caty Carrera, Elena Muiño, Nuria Torres, Jerzy Krupinski, Israel Fernandez-Cadenas*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

16 Citations (Scopus)

Abstract

Oral anticoagulants (OAs) are the recommended drugs to prevent cardiovascular events and recurrence in patients with atrial fibrillation (AF) and cardioembolic stroke. We conducted a literature search to review the current state of OAs pharmacogenomics, focusing on Genome Wide Association Studies (GWAs) in patients treated with vitamin K antagonists (VKAs) and direct oral anticoagulants (DOACs). VKAs: Warfarin, acenocoumarol, fluindione and phenprocoumon have long been used, but their interindividual variability and narrow therapeutic/safety ratio makes their dosage difficult. GWAs have been useful in finding genetic variants associated with VKAs response. The main genes involved in VKAs pharmacogenetics are: VKORC1, CYP2C19 and CYP4F2. Variants in these genes have been included in pharmacogenetic algorithms to predict the VKAs dose individually in each patient depending on their genotype and clinical variables. DOACs: Dabigatran, apixaban, rivaroxaban and edoxaban have been approved for patients with AF. They have stable pharmacokinetics and do not require routine blood checks, thus avoiding most of the drawbacks of VKAs. Except for a GWAs performed in patients treated with dabigatran, there is no Genome Wide pharmacogenomics data for DOACs. Pharmacogenomics could be useful to predict the better clinical response and avoid adverse events in patients treated with anticoagulants, identifying the most appropriate anticoagulant drug for each patient. Current pharmacogenomics data show that the polymorphisms affecting VKAs or DOACs are different, concluding that personalized medicine based on pharmacogenomics could be possible. However, more studies are required to implement personalized medicine in clinical practice with OA and based on pharmacogenetics of DOACs.

Original languageEnglish
Pages (from-to)29238-29258
Number of pages21
JournalOncotarget
Volume9
Issue number49
DOIs
Publication statusPublished - 26 Jun 2018

Keywords

  • DOACs
  • Genetics
  • GWAs
  • Pharmacogenetics
  • VKA

Fingerprint

Dive into the research topics of 'Pharmacogenetic studies with oral anticoagulants. Genomewide association studies in vitamin K antagonist and direct oral anticoagulants'. Together they form a unique fingerprint.

Cite this